Physician profile
James S Brown
NPI 1336231489
$8,361.70
in general payments reported to CMS, 2019-2025
19 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,251 · 2020: $438 · 2021: $806 · 2022: $4,645 · 2023: $450 · 2024: $294 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $4,246.98 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Alcon Vision LLC | $2,165.27 | 2019-2025 | Clareon, Hydrus Microstent |
| Ivantis, INC | $592.26 | 2019-2021 | |
| Abbvie INC. | $332.49 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Allergan, INC. | $222.02 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $150.14 | 2022-2025 | Stellaris, Miebo |
| Ocular Therapeutix, INC. | $130.67 | 2021-2025 | Dextenza |
| Aerie Pharmaceuticals, INC. | $103.89 | 2019-2021 | |
| New World Medical,INC. | $85.19 | 2022-2024 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Johnson & Johnson Surgical Vision, INC. | $84.96 | 2019-2022 | |
| Glaukos Corporation | $65.12 | 2020-2025 | Photrexa Viscous and Photrexa |
| Regeneron Healthcare Solutions, INC. | $38.10 | 2019 | |
| Davol INC. | $29.69 | 2025 | Channel Drain |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.00 | 2021 | |
| Eyepoint US, INC. | $21.44 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.23 | 2019 | |
| Sight Sciences, INC. | $19.17 | 2019 | |
| Harrow Eye, LLC | $18.49 | 2024 | Vevye, Natacyn |
| Sun Pharmaceutical Industries INC. | $14.59 | 2023 | Cequa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.